GSS.AU · Genetic Signatures Limited

-

Please sign in to comment on GSS.AU

1 Comment

Admin

4 years, 1 month ago

Genetic Signatures Limited is currently in a long term downtrend where the price is trading 14.5% below its 200 day moving average.

From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.

Genetic Signatures Limited's total revenue rose by 409.5% to $19M since the same quarter in the previous year.

Its net income has increased by 291.7% to $4M since the same quarter in the previous year.

Finally, its free cash flow grew by 371.5% to $3M since the same quarter in the previous year.

Based on the above factors, Genetic Signatures Limited gets an overall score of 4/5.

Exchange	AU
CurrencyCode	AUD
Sector	Healthcare
Industry	Diagnostics & Research
ISIN	AU000000GSS4

Market Cap	117M
PE Ratio	None
Target Price	0.875
Beta	0.63
Dividend Yield	None

ABOUT

Genetic Signatures Limited

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, SARS-CoV-2 respiratory plus, coronavirus, atypical respiratory, pertussis and PCP, parainfluenza 4, STI genital pathogen, extended spectrum beta-lactamase and carbapenemase producing organisms, viral meningitis, flavivirus dengue alphavirus, flavivirus reflex, dengue typing, and alphavirus reflex Detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.

GSS.AU · Genetic Signatures Limited

-

Genetic Signatures Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Genetic Signatures Limited using a moving average strategy